AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|

26.7 C

New York

Friday, September 11, 2026

St. Johns County Outlines Preparations for Proposed Property Tax Amendment 3

Pacific Coast University for Workplace Health Sciences (PCU-WHS) Launches Canada’s First Course on Measuring the True Economic Impact of Disability Management

NEW YORK CAR DEALERS REMEMBER 9/11 – HOW THEY CAME TOGETHER FOR NEW YORK

Tag: products

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth

Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter

Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

DuraServ Acquires Overhead Door & Fireplace of Montgomery

This latest partnership expands the commercial overhead, residential garage door, and fireplace services available to customers in the Central Alabama area DALLAS, July 18, 2025...

Schooner Stamped Card Sails Into Post Offices

CRYSTAL, Minn., July 18, 2025 /PRNewswire/ -- The U.S. Postal Service issued the schooner stamped card today at the Minnesota Stamp Expo. This new stamped...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

LG’S ENDANGERED SPECIES AWARENESS CAMPAIGN WELCOMES THE PYGMY OWL

Community Votes Shine a Spotlight on the Pygmy Owl in Latest Endangered Species Campaign in New York Times Square Billboard ENGLEWOOD CLIFFS, N.J., July 18,...

VINEYARD VINES PARTNERS WITH ZAC BROWN BAND WITH AN EXCLUSIVE, LIMITED-EDITION CAPSULE COLLECTION

STAMFORD, Conn., July 18, 2025 /PRNewswire/ -- vineyard vines, the iconic lifestyle brand known for its smiling pink whale logo and "Every Day Should...

LOVESAC AND VAN LEEUWEN UNVEIL LIMITED-EDITION COLLABORATION AHEAD OF NATIONAL ICE CREAM DAY

The brands are teaming up to celebrate 10 years of Van Leeuwen's fan-favorite Honeycomb flavor with custom CitySac Covers, $3 scoops, giveaways and a celebration in...

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy^® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsProducts

St. Johns County Outlines Preparations for Proposed Property Tax Amendment 3

Pacific Coast University for Workplace Health Sciences (PCU-WHS) Launches Canada’s First Course on Measuring the True Economic Impact of Disability Management

NEW YORK CAR DEALERS REMEMBER 9/11 – HOW THEY CAME TOGETHER FOR NEW YORK

Tag: products

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

DuraServ Acquires Overhead Door & Fireplace of Montgomery

Schooner Stamped Card Sails Into Post Offices

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

LG’S ENDANGERED SPECIES AWARENESS CAMPAIGN WELCOMES THE PYGMY OWL

VINEYARD VINES PARTNERS WITH ZAC BROWN BAND WITH AN EXCLUSIVE, LIMITED-EDITION CAPSULE COLLECTION

LOVESAC AND VAN LEEUWEN UNVEIL LIMITED-EDITION COLLABORATION AHEAD OF NATIONAL ICE CREAM DAY

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us